Treatment of Neuroendocrine Tumor Liver Metastases

Video

For High-Definition, Click

The symptoms associated with hepatic metastatses from a pancreatic neuroendocrine tumor (NET) can be ameliorated through surgical debulking, suggests Rodney F. Pommier, MD. Moreover, an improvement in long-term outcomes can be achieved by an approximate 90% tumor debulking regardless of the margins, unlike other metastatic tumors. In fact, Pommier notes, many metastatic lesions within the liver can be enucleated without causing higher rates of recurrence.

Outside of surgical options, a variety of other treatment approaches can be utilized for patients with liver metastases, including chemoembolization, radioembolization, and ablation. However, these techniques should be considered secondary to surgery, since they may preclude a successful liver operation, Pommier advises. In general, embolization for liver metastases should be reserved for patients with extensive disease that cannot be treated by surgical debulking.

Related Videos
Video 6 - "Patient Case 2: A 62-Year-Old Woman with Metastatic Rectal Cancer"
Video 5 - "Adverse Events Associated With TAS-102 Plus Bevacizumab in CRC"
Michael J. Overman, MD
Ilyas Sahin, assistant professor, Medicine, Department of Medicine, Division of Hematology & Oncology, University of Florida College of Medicine
Michael J. Overman, MD
Manish A. Shah, MD, director, Gastrointestinal Oncology Program, Weill Cornell Medicine; chief, Solid Tumor Service, co-director, Center for Advanced Digestive Disease, NewYork Presbyterian
Katrina S. Pedersen, MD, MS
Efrat Dotan, MD
In this fifth episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss next steps for research, including vaccination strategies, personalized cellular therapies, and more.
In this fourth episode of OncChats: Leveraging Immunotherapy in GI Malignancies, experts discuss research efforts being made with organoids to address existing questions with immunotherapy and the exploration of multimodality approaches to improve outcomes.